EKOS™ Endovascular System

The most studied device in the space.

With 14 clinical trials published, EKOSTM Endovascular System offers years of proven success.

Real world. Real answers. REAL-PE.

The REAL-PE Analysis is the largest real-world and near real-time dataset evaluating advanced therapies for PE patients.

Pulmonary Embolism

The EKOS™ Endovascular System is the most studied device in the pulmonary embolism space. Since 2014, several major studies have demonstrated clinically significant results in quality of life scores1, mortality2, and long-term safety and efficacy1,3,4 for acute, massive (high risk) and submassive (intermediate risk) PE.

  • EKOS brings 23-26% reduction to the RV/LV ratio – without an increase in bleeding1, 3,4
  • It allows for lower lytic doses – up to 88-92% less than for standard systemic treatment – and shorter delivery duration of the thrombolytic agent5,1
  • It enables shorter average length of hospital stay (3.2 days)than for patients being treated with anticoagulation alone (6.7 days)6

Access full clinical overview of EKOS ultrasound-assisted thrombolysis for Pulmonary Embolism.

Deep Vein Thrombosis

The EKOSTM Endovascular System quickly restores blood flow, potentially reducing the risk of pulmonary embolism and post-thrombotic syndrome (PTS).

  • Up to 50% of DVT patients have PE7
  • Removes thrombus more completely compared to CDT8
  • Reduces post-thrombotic syndrome9
In the ACCESS PTS study, 73 patients with chronic DVT treated with a regimen of both balloon dilatation and EKOSTM therapy saw a significant reduction in Villalta Score of 49% and a 36% improvement in VEINS-QOL at one year.10

Completed studies on EKOS™ for DVT are:

CAVA: A randomised controlled multicenter trial comparing ultrasound-accelerated catheter-directed thrombolysis, combined with standard anticoagulant therapy, with standard anticoagulant therapy alone, for acute primary iliofemoral deep vein thrombosis (Level 1) A.

ACCESS PTS: ACCElerated ThrombolySiS for Post-Thrombotic Syndrome Using the EKOS™ System (Level 2) Chronicdvtstudy.com

Arterial Occlusion

The EKOSTM Endovascular System improves on standard CDT by safely accelerating drug penetration, even in difficult-to-reach areas:

  • Shorter treatment times11
  • Lower 30-day amputation rate11
  • Lower bleeding rates when compared to CDT11
  • Higher complete dissolution rate of thrombus11
  • Shorter hospital stays11

Completed trials on EKOSTM for PAO are: 

DUET: Dutch randomised trial comparing standard catheter-directed thrombolysis versus ultrasound-accelerated thrombolysis for thrombo-embolic infra-inguinal.